These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
266 related items for PubMed ID: 34218802
1. Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial. Alhalabi M, Alassi MW, Alaa Eddin K, Cheha K. BMC Infect Dis; 2021 Jul 04; 21(1):642. PubMed ID: 34218802 [Abstract] [Full Text] [Related]
2. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial. Liou JM, Jiang XT, Chen CC, Luo JC, Bair MJ, Chen PY, Chou CK, Fang YJ, Chen MJ, Chen CC, Lee JY, Yang TH, Yu CC, Kuo CC, Chiu MC, Chen CY, Shun CT, Hu WH, Tsai MH, Hsu YC, Tseng CH, Chang CY, Lin JT, El-Omar EM, Wu MS, Taiwan Gastrointestinal Disease and Helicobacter Consortium. Lancet Gastroenterol Hepatol; 2023 Mar 04; 8(3):228-241. PubMed ID: 36549320 [Abstract] [Full Text] [Related]
4. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy. Song Z, Zhou L, Zhang J, He L, Bai P, Xue Y. Dig Liver Dis; 2016 May 04; 48(5):506-511. PubMed ID: 26847964 [Abstract] [Full Text] [Related]
5. Efficacy of a 2-week therapy with levofloxacin concomitant versus a levofloxacin sequential regimen for Helicobacter pylori infection in the Syrian population: a study protocol for randomized controlled trial. Alhalabi M, Almokdad R. Trials; 2024 Jan 15; 25(1):55. PubMed ID: 38225650 [Abstract] [Full Text] [Related]
6. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection. Fu W, Song Z, Zhou L, Xue Y, Ding Y, Suo B, Tian X, Wang L. Dig Dis Sci; 2017 Jun 15; 62(6):1580-1589. PubMed ID: 28391418 [Abstract] [Full Text] [Related]
7. Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial). Tungtrongchitr N, Bongkotvirawan P, Ratana-Amornpin S, Siramolpiwat S, Eiamsitrakoon T, Gamnarai P, Wongcha-Um A, Yamaoka Y, Pawa KK, Vilaichone RK. Sci Rep; 2024 Apr 18; 14(1):8986. PubMed ID: 38637591 [Abstract] [Full Text] [Related]
8. Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori. Kadayifci A, Uygun A, Polat Z, Kantarcioğlu M, Kılcıler G, Başer O, Ozcan A, Emer O. Turk J Gastroenterol; 2012 Feb 18; 23(1):8-13. PubMed ID: 22505373 [Abstract] [Full Text] [Related]
10. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients. Wang Z, Wu S. Singapore Med J; 2012 Apr 18; 53(4):273-6. PubMed ID: 22511052 [Abstract] [Full Text] [Related]
12. Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori. Wu TS, Hsu PI, Kuo CH, Hu HM, Wu IC, Wang SSW, Chen YH, Wu DC, Su WW, Kuo FC. J Dig Dis; 2017 Sep 18; 18(9):537-542. PubMed ID: 28644575 [Abstract] [Full Text] [Related]
13. Efficacy of two different dosages of levofloxacin in curing Helicobacter pylori infection: A Prospective, Single-Center, randomized clinical trial. Gan HY, Peng TL, Huang YM, Su KH, Zhao LL, Yao LY, Yang RJ. Sci Rep; 2018 Jun 13; 8(1):9045. PubMed ID: 29899426 [Abstract] [Full Text] [Related]
14. Vonoprazan Dual or Triple Therapy Versus Bismuth-Quadruple Therapy as First-Line Therapy for Helicobacter pylori Infection: A Three-Arm, Randomized Clinical Trial. Cheung KS, Lyu T, Deng Z, Han S, Ni L, Wu J, Tan JT, Qin J, Ng HY, Leung WK, Seto WK. Helicobacter; 2024 Jun 13; 29(5):e13133. PubMed ID: 39244723 [Abstract] [Full Text] [Related]
15. 14-day tailored PCR-guided triple therapy versus 14-day non-Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open-label randomized noninferiority controlled trial. Amiot A, Hacoon J, Heluwaert F, Mion F, Lamarque D, Moussata D, Mimouni M, Delchier JC, Durand-Zaleski I, Audureau E, Bastuji-Garin S, HEPYSE Study Group. Helicobacter; 2024 Jun 13; 29(2):e13076. PubMed ID: 38680067 [Abstract] [Full Text] [Related]
16. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, Chen MJ, Chen CC, Tseng CH, Hsu YC, Lee JY, Yang TH, Luo JC, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hu WH, Chen YN, Sheu BS, Lin JT, Wu JY, El-Omar EM, Wu MS, Taiwan Gastrointestinal Disease and Helicobacter Consortium. Lancet; 2016 Nov 12; 388(10058):2355-2365. PubMed ID: 27769562 [Abstract] [Full Text] [Related]
18. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Liu KS, Hung IF, Seto WK, Tong T, Hsu AS, Lam FY, But DY, Wong SY, Leung WK. Gut; 2014 Sep 12; 63(9):1410-5. PubMed ID: 24295850 [Abstract] [Full Text] [Related]
19. Bismuth, rabeprazole, amoxicillin, and doxycycline as first-line Helicobacter pylori therapy in clinical practice: A pilot study. Gu L, Li S, He Y, Chen Y, Jiang Y, Peng Y, Liu X, Yang H. Helicobacter; 2019 Aug 12; 24(4):e12594. PubMed ID: 31119830 [Abstract] [Full Text] [Related]
20. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial. Hsu PI, Tsai FW, Kao SS, Hsu WH, Cheng JS, Peng NJ, Tsai KW, Hu HM, Wang YK, Chuah SK, Chen A, Wu DC. Am J Gastroenterol; 2017 Sep 12; 112(9):1374-1381. PubMed ID: 28719592 [Abstract] [Full Text] [Related] Page: [Next] [New Search]